| Authors: |
Oliver M; Centre for Human Drug Research, Leiden, The Netherlands; Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands., Molnarova M; SCARLETRED Holding GmbH, Vienna, Austria., Bergmans M; Centre for Human Drug Research, Leiden, The Netherlands., Ranjan R; SCARLETRED Holding GmbH, Vienna, Austria., Exadaktylos V; Centre for Human Drug Research, Leiden, The Netherlands., Niemeyer van der Kolk T; Centre for Human Drug Research, Leiden, The Netherlands., Seyger MMB; Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands., Wee L; MAASTRO (Dept of Radiation Oncology), GROW Research Institute of Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Balak DMW; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands. Electronic address: d.m.w.balak@lumc.nl., van Doorn MBA; Centre for Human Drug Research, Leiden, The Netherlands; Department of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands., Rissmann R; Centre for Human Drug Research, Leiden, The Netherlands; Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands; Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands. Electronic address: rrissmann@chdr.nl., Schnidar H; SCARLETRED Holding GmbH, Vienna, Austria., Rousel J; Centre for Human Drug Research, Leiden, The Netherlands; Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. |